U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07003555) titled 'Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration' on May 23.
Brief Summary: This is a multicenter, open-label, non-randomized, single-arm clinical trial. Patients with relapsed/refractory multiple myeloma accompanied by extramedullary infiltration will receive BCMA - CD19 CAR-T cell therapy.
The primary objective is to prospectively evaluate the safety of dual-targeting BCMA and CD19 CAR - T cell therapy for extramedullary infiltration in relapsed/refractory multiple myeloma. The primary endpoints are to assess the type and incidence of dose-limiting toxicity (DLT) within one month after the infusi...